Comparison of efficacy and safety of platinum-based chemotherapy as first-line therapy between B3 thymoma and thymic carcinoma

被引:0
|
作者
Hao, Y. [1 ]
Si, J. [2 ]
Jin, J. [3 ]
Wei, J. [3 ]
Xiang, J. [2 ]
Xu, C. [4 ]
Song, Z. [3 ]
机构
[1] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China
[2] Zhejiang Chinese Med Univ, Hangzhou, Peoples R China
[3] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[4] Nanjing Univ, Sch Med, Fuzhou, Peoples R China
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
220P
引用
收藏
页码:S157 / S157
页数:1
相关论文
共 50 条
  • [1] Comparison of Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy between B3 Thymoma and Thymic Carcinoma
    Hao, Yue
    Si, Jinfei
    Jin, Jianan
    Wei, Jingwen
    Xiang, Jing
    Xu, Chunwei
    Song, Zhengbo
    CURRENT ONCOLOGY, 2022, 29 (12) : 9452 - 9460
  • [2] EFFICACY AND SAFETY OF FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH POST-OPERATIVE RECURRENCE AFTER PLATINUM-BASED ADJUVANT CHEMOTHERAPY
    Muraki, K.
    Imai, H.
    Shukuya, T.
    Ohhashi, R.
    Koyama, R.
    Mori, T.
    Murakami, H.
    Takahashi, T.
    Yamamoto, N.
    Takahashi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 148 - 148
  • [3] Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis
    Arunachalam, Ashwini
    Zhang, Ina
    Zhao, Bin
    Frederickson, Andrew M.
    Pietanza, M. Catherine
    LUNG CANCER, 2023, 176 : 132 - 139
  • [4] Clinical outcomes for advanced thymoma patients receiving platinum-based chemotherapy as first-line treatment
    Hao, Y.
    Sun, W.
    Zeng, X.
    Shi, Z.
    Wang, W.
    Xu, C.
    Song, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S157 - S157
  • [5] First-line PD-1 Inhibitor plus Chemotherapy versus Platinum-based Chemotherapy for Patients with Advanced Thymic Carcinoma
    Liu, M.
    Zhao, J.
    Liu, Z.
    Hou, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S127 - S127
  • [6] Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
    Minato, Akinori
    Ohno, Daichi
    Murooka, Kazuki
    Okumura, Yutaka
    Takaba, Tomohisa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Harada, Kenichi
    Fujimoto, Naohiro
    IN VIVO, 2024, 38 (04): : 1927 - 1934
  • [7] Efficacy and Safety of First-Line Platinum-Based Doublet Chemotherapy in Advanced Primary Pulmonary Salivary Gland Tumors (PSGTs)
    Shi, Zheng
    Zeng, Xiaohong
    Sun, Wei
    Xu, Manyi
    Shao, Keda
    Wei, Jingwen
    Xu, Chunwei
    Song, Zhengbo
    CANCER INVESTIGATION, 2024, 42 (09) : 793 - 800
  • [8] THE EFFECTS OF PLATINUM-BASED CHEMOTHERAPY RECHALLENGE FOR ADVANCED UROTHELIAL CARCINOMA PATIENTS WHOSE DISEASE PROGRESSED AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY AND PEMBROLIZUMAB
    Yumioka, Tetsuya
    Honda, Masashi
    Shimizu, Ryutaro
    Teraoka, Shogo
    Kimura, Yusuke
    Iwamoto, Hideto
    Morizane, Shuichi
    Hikita, Katsuya
    Takenaka, Atsushi
    JOURNAL OF UROLOGY, 2021, 206 : E1001 - E1002
  • [9] Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.
    Necchi, Andrea
    Mariani, Luigi
    Lo Vullo, Salvatore
    Raggi, Daniele
    Giannatempo, Patrizia
    Bamias, Aristotelis
    Crabb, Simon J.
    Bellmunt, Joaquim
    Yu, Evan Y.
    Niegisch, Guenter
    Vaishampayan, Ulka N.
    Theodore, Christine
    Berthold, Dominik R.
    Srinivas, Sandy
    Sridhar, Srikala S.
    Plimack, Elizabeth R.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Galsky, Matthew
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy
    Weitzner, Omar
    Yagur, Yael
    Kadan, Yfat
    Beiner, Mario E.
    Fishman, Ami
    Ben Ezry, Emilie
    Komem, Daphna Amitai
    Helpman, Limor
    ONCOLOGIST, 2019, 24 (12): : E1471 - E1475